Advertisement

Diagnostik kardiovaskulärer Krankheiten

  • Evangelos Giannitsis
  • Ingolf Schimke
  • Peter B. Luppa
  • Dirk Peetz

Zusammenfassung

Der bevorzugte Biomarker in der Herzinfarktdiagnostik ist das quantitativ im Serum gemessene kardiale Troponin (cTn) wegen seiner Gewebespezifität. Bei Verwendung hochsensitiver cTn-Assays wird die Bestimmung weiterer Marker wie Myoglobin, CK-MB Masse, FABP nicht empfohlen, da diese Biomarker keinen diagnostischen Zusatznutzen bringen. Hochsensitive cTn-Assays werden bislang von zwei POCT-Benchtop-Geräten angeboten. Für die labormedizinische Begleitung der chronischen Herzinsuffizienz stehen heute mit dem BNP und dem NT-pro-BNP Marker zur Verfügung, deren Einsatz von Europäischen und Amerikanischen Fachgesellschaften für Screening und Diagnostik der Herzinsuffizienz empfohlen wird. POCT-Methoden zur Messung sind bereits entwickelt worden.

Literatur

  1. 1.
    Altintas Z, Fakanya W, Tothill I (2014) Cardiovascular disease detection using bio-sensing techniques. Talanta 128: 177–186Google Scholar
  2. 2.
    Amundson B, Apple F (2015) Cardiac troponin assays: a review of quantitative point-of care devices and their efficacy in the diagnosis of myocardial infarction. Clin Chem Lab Med 53: 665–676Google Scholar
  3. 3.
    Antman EM, Anbe DT, Armstrong PW et al. (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction – executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 44: 671–719; erratum in: J Am Coll Cardiol 2005; 45: 1376Google Scholar
  4. 4.
    Anwaruddin S, Lloyd-Jones DM, Baggish A et al. (2006) Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 47: 91–97Google Scholar
  5. 5.
    Apple FS, Wu AHB, Jaffe AS (2002) European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: How to use existing assays clinically and for clinical trials. J Am Heart 144: 981–986Google Scholar
  6. 6.
    AWMF online (2015) Diagnostik und Therapie der Venenthrombose und der Lungenembolie. Leitlinien Angiologie 2015; www.leitlinien.net. Letzte Überarbeitung: 10/2015
  7. 7.
    Braunwald E, Antman EM, Beasley JW et al. (2002) ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction – summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 40:1366–1374Google Scholar
  8. 8.
    Christenson RH on behalf of the Committee on Evidence Based Laboratory Medicine of the International Federation for Clinical Chemistry Laboratory Medicine (2007) Evidence-based laboratory medicine – a guide for critical evaluation of in vitro laboratory testing. Ann Clin Biochem 44: 111–130Google Scholar
  9. 9.
    Collinson P, Goodacre S, Gaze D, Gray A (2012) Very early diagnosis of chest pain by point-of-care testing: comparison of the diagnostic efficiency of a panel of cardiac biomarkers compared with troponin measurment alsone in the RATPAC trial. Heart 98: 312–318Google Scholar
  10. 10.
    Goodacre S, Bradburn M, Fitzgerald P, Cross E, Collinson P, Gray A, Hall AS (2011) The RATPAC (Randomised Assessment of Treatment using Panel Assay of Cardiac markers) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. Health Technol Assess 15:1–102Google Scholar
  11. 11.
    Hunt SA, Abraham WT, Chin MH et al. (2005) American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing committee to update the 2001 guidelines for the evaluation and management of heart failure), developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112: 154–235Google Scholar
  12. 12.
    Karakas M, Januzzi JL Jr, Meyer J, Lee H, Schlett CL, Truong QA et al. (2011) Copeptin does not add diagnostic information to high-sensitivity troponin T in low- to intermediate-risk patients with acute chest pain: Results from the rule out myocardial infarction by computed tomography (ROMICAT) study. Clin Chem 57:1137–45Google Scholar
  13. 13.
    Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E et al. (2009) Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 361:868–877Google Scholar
  14. 14.
    Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp L, Ojeda FM et al. (2010) Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 55:2096–2106Google Scholar
  15. 15.
    Korley FK, Jaffe AS (2013) Preparing the United States for high-sensitivity cardiac troponin assays. J Am Coll Cardiol 61: 1753–1758Google Scholar
  16. 16.
    Lee-Lewandroski E, Januzzi JJ, Grisson R, Mohammed A, Lewandrowski G, Lewandrowski K (2011) Evaluation of first-draw whole blood, point-of-care cardiac markers in the context of the universal definition of myocardial infarction. Arch Pathol Lab Med 135: 459–463Google Scholar
  17. 17.
    McMurray JJ, Stewart S (2000) Epidemiology, aetiology, and prognosis of heart failure. Heart 83: 596–602Google Scholar
  18. 18.
    Panteghini M, Pagani F, Yeo KT et al. (2004) Committee on Standardization of Markers of Cardiac Damage of the IFCC. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem 50: 327–332Google Scholar
  19. 19.
    Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG et al. (2009) Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 54:60–68Google Scholar
  20. 20.
    Remme WJ, Swedberg K (2001) Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22: 1527–1560Google Scholar
  21. 21.
    Ryan RJ, Lindsell CJ, Hollander JE, O’Neil B, Jackson R, Schreiber D, Christenson R, Gibler WB (2009) A multicenter randomized controlled trial comparing central laboratory and point-of-care cardiac marker testing strategies: the Disposition Impacted by Serial Point of Care Markers in Acute Coronary Syndromes (DISPO-ACS) trial. Ann Emerg Med 53:321–328Google Scholar
  22. 22.
    Roffi M et al., for the Task Force of the European Society of Cardiology (ESC) (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal) 37: 267–315Google Scholar
  23. 23.
    Sandoval Y, Apple FS (2014) The global need to define normality: the 99th percentile value of cardiac troponin. Clin Chem 60: 455–462Google Scholar
  24. 24.
    Tang WH, Francis GS, Morrow DA et al. (2007) National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation 116: 99–109Google Scholar
  25. 25.
    Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction (2012) Third universal definition of myocardial infarction. Glob Heart 7:275–295Google Scholar
  26. 26.
    Vafaie M, Biener M, Mueller M, Abu Sharar H, Hartmann O, Hertel S, Katus HA, Giannitsis E (2015) Addition of copeptin improves diagnostic performance of point-of-care testing (POCT) for cardiac troponin T in early rule-out of myocardial infarction – A pilot study. Int J Cardiol 198:26–30Google Scholar
  27. 27.
    Venge P, Öhberg C, Flodin M, Lindahl B (2010) Early and late outcome prediction of death in the emergency room setting by point-of-care and laboratory assays of cardiac troponin I. Am Heart J 160: 835–841Google Scholar

Copyright information

© Springer-Verlag GmbH Deutschland 2017

Authors and Affiliations

  • Evangelos Giannitsis
    • 1
  • Ingolf Schimke
    • 2
  • Peter B. Luppa
    • 3
  • Dirk Peetz
    • 4
  1. 1.Thoraxklinik am Universitätsklinikum HeidelbergHeidelbergDeutschland
  2. 2.Medizinische Klinik (Kardiologie)Charité – Universitätsmedizin BerlinBerlinDeutschland
  3. 3.Institut für Klinische Chemie und PathobiochemieKlinikum rechts der TU MünchenMünchenDeutschland
  4. 4.Institut für LaboratoriumsmedizinHELIOS Klinikum Berlin-BuchBerlinDeutschland

Personalised recommendations